LTRN · Insider Trading
Lantern Pharma Inc. Common Stock
Every open-market purchase and sale reported by LTRN officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-05-14 | D Jeffrey Keyser | Director | Buy | +48,544 | +$100.00K |
| 2026-05-14 | Lee Troy Schalop | Director | Buy | +48,544 | +$100.00K |
| 2026-01-13 | Vijay Chandru | Director | A | +42,307 deriv. | — |
| 2026-01-13 | Lee Troy Schalop | Director | A | +43,460 deriv. | — |
| 2026-01-13 | D Jeffrey Keyser | Director | A | +53,844 deriv. | — |
| 2026-01-13 | Maria-Luisa Maccecchini | Director | A | +46,152 deriv. | — |
| 2026-01-13 | David S. Silberstein | Director | A | +42,307 deriv. | — |
| 2025-12-22 | David R. Margrave | Chief Financial Officer | A | +20,000 deriv. | — |
| 2025-12-22 | Kishor G. Bhatia | Chief Scientific Officer | A | +10,000 deriv. | — |
| 2025-09-23 | Panna Sharma | President & CEO | MIXED | — | — |
| 2025-09-23 | D Jeffrey Keyser | Director | MIXED | — | — |
| 2025-09-23 | David S. Silberstein | Director | MIXED | — | — |
| 2025-09-23 | David R. Margrave | Chief Financial Officer | MIXED | — | — |
| 2025-09-23 | Vijay Chandru | Director | MIXED | — | — |
| 2025-09-23 | Kishor G. Bhatia | Chief Scientific Officer | MIXED | — | — |
| 2025-08-20 | Lee Troy Schalop | Director | A | +5,000 deriv. | — |
| 2025-06-13 | Leslie W. Kreis | 10%+ Owner | Sell | −160,000 | −$494.40K |
| 2025-06-13 | BIOS Fund II NT, LP | 10%+ Owner | Sell | −400,000 | −$1.24M |
| 2025-06-13 | Leslie W. Kreis | 10%+ Owner | Sell | −246,452 | −$833.09K |
| 2025-06-13 | BIOS Fund II QP, LP | 10%+ Owner | Sell | −616,130 | −$2.08M |
| 2025-05-29 | Leslie W. Kreis | 10%+ Owner | Sell | −224,948 | −$673.68K |
| 2025-05-29 | BIOS Fund I, LP | 10%+ Owner | Sell | −562,370 | −$1.68M |
| 2024-07-26 | D Jeffrey Keyser | Director | X | +3,832 | +$11.99K |
| 2024-07-17 | D Jeffrey Keyser | Director | A | +5,000 deriv. | — |
| 2024-07-17 | Panna Sharma | President and CEO | A | +70,000 deriv. | — |
| 2024-07-17 | Maria-Luisa Maccecchini | Director | A | +5,000 deriv. | — |
| 2024-07-17 | David R. Margrave | Chief Financial Officer | A | +52,000 deriv. | — |
| 2024-07-17 | Kishor G. Bhatia | Chief Scientific Officer | A | +35,000 deriv. | — |
| 2024-07-17 | David S. Silberstein | Director | A | +10,000 deriv. | — |
| 2024-07-17 | Vijay Chandru | Director | A | +10,000 deriv. | — |
| 2024-05-28 | BP Directors, LP | 10%+ Owner | Sell | −120,000 | −$756.40K |
| 2024-05-28 | BIOS Advisors GP, LLC | 10%+ Owner | Sell | −300,000 | −$1.89M |
| 2024-02-29 | Bios Equity Partners II, LP | 10%+ Owner | Sell | −1,440,000 | −$6.76M |
| 2024-02-29 | Cavu Management, LP | 10%+ Owner | Sell | −576,000 | −$2.71M |
| 2024-01-19 | BIOS Fund II NT, LP | 10%+ Owner | MIXED | +201,320 | +$19 |
| 2024-01-19 | Cavu Advisors, LLC | 10%+ Owner | MIXED | +80,528 | +$8 |
| 2023-12-01 | Cavu Management, LP | 10%+ Owner | Sell | −581,392 | −$2.00M |
| 2023-12-01 | BIOS Fund II NT, LP | 10%+ Owner | Sell | −1,453,480 | −$5.00M |
| 2022-11-09 | Leslie W. Kreis | 10%+ Owner | Sell | −1,400,000 | −$6.16M |
| 2022-11-09 | BIOS Advisors GP, LLC | 10%+ Owner | Sell | −3,500,000 | −$15.40M |
| 2022-10-24 | Maria-Luisa Maccecchini | Director | A | +3,200 deriv. | — |
| 2022-09-07 | Cavu Advisors, LLC | 10%+ Owner | MIXED | +104,372 | +$1 |
| 2022-09-07 | BIOS Fund I QP, LP | 10%+ Owner | MIXED | +260,930 | +$1 |
| 2022-08-09 | Panna Sharma | President and CEO | A | +100,000 deriv. | — |
| 2022-03-21 | Cavu Advisors, LLC | 10%+ Owner | X | +862,011 | +$138.07B |
| 2021-11-08 | Vijay Chandru | Director | A | +3,200 deriv. | — |
| 2021-11-08 | Franklyn G Prendergast | Director | A | +3,200 deriv. | — |
| 2021-11-08 | David S. Silberstein | Director | A | +3,200 deriv. | — |
| 2021-11-08 | D Jeffrey Keyser | Director | A | +3,200 deriv. | — |
| 2021-11-08 | Leslie W. Kreis | Director | A | — | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| BIOS Fund I, LP | 10%+ Owner | 354,630 | $221.22K |
| BIOS Fund II QP, LP | 10%+ Owner | 125,330 | $78.18K |
| Leslie W. Kreis | Director | 125,330 | $78.18K |
| D Jeffrey Keyser | Director | 94,303 | $58.83K |
| BIOS Fund II NT, LP | 10%+ Owner | 49,957 | $31.16K |
| Lee Troy Schalop | Director | 48,544 | $30.28K |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the LTRN quote page; the site-wide leaderboard is on the insider transactions hub.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.